Abstract 329: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Institut Curie
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148659185
Cites:
Cited by:
Related to: